2022-23 ASH Update - April 6, 2023

1 Start 2 Complete

2022-23 Annual Updates in Management of Hematologic Malignancies - ASH 2022 Update

April 6, 2023

How well were the overall course objectives met? *

Rating (1=low, 5=high)

	1	2	3	4	5
Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma	Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma - 1	Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma - 2	Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma - 3	Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma - 4	Provide updates in the management of acute leukemia, myloproliferative neoplasms, AML, MDS, lymphoma, and myeloma - 5
Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS)	Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS) - 1	Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS) - 2	Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS) - 3	Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS) - 4	Increased knowledge of the changing definitions of acute myeloid leukemia (AML) and myelodysplasia (MDS) - 5
Discuss the management of immunotherapies in myeloma and lymphoma	Discuss the management of immunotherapies in myeloma and lymphoma - 1	Discuss the management of immunotherapies in myeloma and lymphoma - 2	Discuss the management of immunotherapies in myeloma and lymphoma - 3	Discuss the management of immunotherapies in myeloma and lymphoma - 4	Discuss the management of immunotherapies in myeloma and lymphoma - 5
Define the application of novel therapies for patients with blood cancers to improve their survival	Define the application of novel therapies for patients with blood cancers to improve their survival - 1	Define the application of novel therapies for patients with blood cancers to improve their survival - 2	Define the application of novel therapies for patients with blood cancers to improve their survival - 3	Define the application of novel therapies for patients with blood cancers to improve their survival - 4	Define the application of novel therapies for patients with blood cancers to improve their survival - 5

As a result of my participation in this CME activity: *

1 strongly disagree 2 disagree 3 unsure 4 agree 5 strongly agree

	1	2	3	4	5
My knowledge increased.	My knowledge increased. - 1	My knowledge increased. - 2	My knowledge increased. - 3	My knowledge increased. - 4	My knowledge increased. - 5
My ability to provide appropriate care to my patients improved.	My ability to provide appropriate care to my patients improved. - 1	My ability to provide appropriate care to my patients improved. - 2	My ability to provide appropriate care to my patients improved. - 3	My ability to provide appropriate care to my patients improved. - 4	My ability to provide appropriate care to my patients improved. - 5
I feel a decreased sense of professional isolation.	I feel a decreased sense of professional isolation. - 1	I feel a decreased sense of professional isolation. - 2	I feel a decreased sense of professional isolation. - 3	I feel a decreased sense of professional isolation. - 4	I feel a decreased sense of professional isolation. - 5
Relevance to your practice.	Relevance to your practice. - 1	Relevance to your practice. - 2	Relevance to your practice. - 3	Relevance to your practice. - 4	Relevance to your practice. - 5

What are your key take-aways? *

Will you make a change in your practice? *

Yes

What changes do you plan to make? *

What are some relevant challenges that you face in your practice? *

Was the material presented in a manner that was free from commercial bias? *

Yes

Please explain the commercial bias *

Leave this field blank

You are here

2022-23 ASH Update - April 6, 2023

2022-23 Annual Updates in Management of Hematologic Malignancies - ASH 2022 Update

April 6, 2023